about
Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesisHigh-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinasePI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture.The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease ProgressionThe mutational landscape of hepatocellular carcinomaElectrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomicsA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesThe Structure of the MAP2K MEK6 Reveals an Autoinhibitory DimerGenomics, evolution, and crystal structure of a new family of bacterial spore kinasesAn isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinaseConservation, variability and the modeling of active protein kinasesA predictive phosphorylation signature of lung cancerA novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationMetabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activityCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsSorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cellsKnowledge-based fragment binding predictionDeciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin ActionStructures of influenza A proteins and insights into antiviral drug targets.Asymmetric cancer cell division regulated by AKTA bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activityKinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.The kinase Mirk is a potential therapeutic target in osteosarcoma.Isoform-specific upregulation of palladin in human and murine pancreas tumors.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsPhotocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MSIdentification of novel signaling components in N,N'-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma by quantitative phosphoproteomics.7,3',4'-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesProperties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.Expression of proto-oncogene KIT is up-regulated in subset of human meningiomasMyelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.Multiple signal pathways in obesity-associated cancer.Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis.
P2860
Q21245763-DCCA26BB-639F-4F2A-8AFF-1446DAE345ABQ21563543-A6D49EC8-20FC-4D08-BDE5-0A220EF97D74Q22000770-167F9492-DD49-4BED-A5EF-B5D8201B8A4BQ26744831-E48C6DED-8204-43CD-97F4-77E9B15E2F3BQ26777478-CE343444-0654-4ECD-A366-16B80E238009Q26822552-95A5C097-041A-45F1-9CCC-D9EB2492FC3CQ26824462-EBE412A8-353A-46DE-A76C-2FE086730F52Q27652488-6FF74E65-3570-4948-BEB9-9CF018D2C47EQ27653414-7D105F2B-5A6F-46DC-9861-3EBB940EAC86Q27658966-CB08B2C0-73BA-4C67-918C-720F31D6DB45Q28276857-19448CD8-6247-4BE0-9234-1AF5C2B1E16AQ28469309-D32E1833-10A5-41C9-A7AD-BE60D81DAD23Q28472058-2A587CE1-8DDC-41FD-814B-AB0CC7D5AE17Q28480605-D474C7F9-386B-4DA0-B933-F4CECDD972F7Q28481438-E408FFC9-ED10-4291-A12F-E06A2AADBDD7Q28484913-E23EB701-2A92-4667-8B3A-C0D6CA34144DQ28533484-2F971E4F-235F-49D4-AF2D-73B039782106Q28538204-A48B853C-D949-43AB-9FC2-207D2C7E601BQ28548411-AE959FD3-8AFC-40EF-8417-22309F5B5320Q30387969-CC047C81-58B4-4293-A343-AE82B6D2B4A9Q30503288-4D3C8954-BB5D-4964-92F0-0147EFBE2061Q30981853-79F15971-E8E7-418D-94E8-2877C3E764B6Q33268625-B7EF9625-CAB4-4A7D-B431-C8AFF2AAFED6Q33431755-A400A437-23BA-4C6B-9B60-14EE064AD083Q33445369-7C32B73A-7D69-4A73-8946-E8B4A2C34423Q33521423-A4F9A548-7BC8-4C60-BF88-A8AB284F268DQ33570447-9850A303-DE56-4C37-8565-CB4F786DB2ADQ33622982-2ED537A3-D105-4879-B16D-C9F449208D1EQ33699182-470D547F-39B0-4BB9-99C2-43218DFFDF30Q33913996-877FDFDC-697D-4BD6-8285-F7AACFFE1F63Q33967370-608A0B60-45AF-4D70-A3BD-E2D976D425CDQ34088265-C0DEAB35-AB08-4CFC-895F-DCCC833E200EQ34139691-98D2D1EE-E2C3-495F-87C1-5225EDA6D555Q34203720-B33FB854-5066-4E9F-BD5B-1607D80196AEQ34294309-17C64300-D105-4C05-9CEB-1CD59E412715Q34612979-0BB560AE-FAC9-4141-93CA-2863F0253006Q34633750-AF68B1FA-441A-4B31-BE53-CC927ECEA647Q34787415-1313D779-6229-4293-87C9-B8474C166EE3Q34953306-88932029-A492-479D-9B99-E52C4F8926FAQ35069229-1AFC6E86-862F-45F7-90B5-A6EA0DDC191B
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Mechanisms of drug inhibition of signalling molecules.
@ast
Mechanisms of drug inhibition of signalling molecules.
@en
type
label
Mechanisms of drug inhibition of signalling molecules.
@ast
Mechanisms of drug inhibition of signalling molecules.
@en
prefLabel
Mechanisms of drug inhibition of signalling molecules.
@ast
Mechanisms of drug inhibition of signalling molecules.
@en
P2860
P356
P1433
P1476
Mechanisms of drug inhibition of signalling molecules.
@en
P2093
Jessie M English
Judith S Sebolt-Leopold
P2860
P2888
P304
P356
10.1038/NATURE04874
P407
P577
2006-05-01T00:00:00Z
P5875
P6179
1005734911